Canopy Growth Corp Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Canopy Growth Corp (CGC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of 1.12 CAD/shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-07
- Canopy Growth Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was 1.12 CAD/shares, a 28.66% decline year-over-year.
- Canopy Growth Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was 1.57 CAD/shares, a 80.50% decline year-over-year.
- Canopy Growth Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-06-30 was 8.05 CAD/shares, a 111.84% increase year-over-year.
- Canopy Growth Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-06-30 was 3.80 CAD/shares, a 35.71% increase year-over-year.
- Canopy Growth Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2026 was 1.60 CAD/shares, a 73.06% decline from fiscal 2025.
- Canopy Growth Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was 5.94 CAD/shares, a 53.49% increase from fiscal 2024.
- Canopy Growth Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was 3.87 CAD/shares, a 86.75% decline from fiscal 2023.
- Canopy Growth Corp share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was 29.20 CAD/shares, a 69.87% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 1.12 CAD/shares 10-Q · filed 2026-08-07 | |||||
| 2026-03-31 | 1.60 CAD/shares 10-K · filed 2026-06-15 | |||||
| 2025-12-31 | 1.31 CAD/shares 10-Q · filed 2026-02-06 | |||||
| 2025-09-30 | 1.57 CAD/shares 10-Q · filed 2025-11-07 | |||||
| 2025-06-30 | 1.57 CAD/shares 10-Q · filed 2026-08-07 | |||||
| 2025-03-31 | 5.94 CAD/shares 10-K · filed 2026-06-15 | |||||
| 2024-12-31 | 0.00 CAD/shares 10-Q · filed 2026-02-06 | |||||
| 2024-09-30 | 7.17 CAD/shares 10-Q · filed 2025-11-07 | |||||
| 2024-06-30 | 8.05 CAD/shares 10-Q · filed 2025-08-08 | |||||
| 2024-03-31 | 3.87 CAD/shares 10-K · filed 2026-06-15 | |||||
| 2023-12-31 | 5.33 CAD/shares 10-Q · filed 2025-02-07 | |||||
| 2023-06-30 | 3.80 CAD/shares 10-Q · filed 2024-08-09 | 0.38 CAD/shares 10-Q · filed 2023-08-09 | ||||
| 2023-03-31 | 29.20 CAD/shares 10-K · filed 2025-05-30 | 2.92 CAD/shares 10-K · filed 2023-06-22 | ||||
| 2022-12-31 | 3.34 CAD/shares 10-Q · filed 2023-02-09 | 33.40 CAD/shares 10-Q · filed 2024-02-09 | ||||
| 2022-09-30 | 2.17 CAD/shares 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | 2.80 CAD/shares 10-Q · filed 2023-08-09 | |||||
| 2022-03-31 | 96.90 CAD/shares 10-K · filed 2024-05-30 | 9.69 CAD/shares 10-K · filed 2022-05-31 | ||||
| 2021-12-31 | 7.55 CAD/shares 10-Q · filed 2023-02-09 | 7.55 CAD/shares 10-Q · filed 2022-02-09 | ||||
| 2021-06-30 | 17.25 CAD/shares 10-Q · filed 2022-08-09 | |||||
| 2021-03-31 | 15.24 CAD/shares 10-K · filed 2023-06-22 | |||||
| 2020-12-31 | 23.53 CAD/shares 10-Q · filed 2022-02-09 | |||||
| 2020-09-30 | 12.85 CAD/shares 10-Q · filed 2021-11-08 | 12.85 CAD/shares 10-Q · filed 2020-11-09 | ||||
| 2020-06-30 | 12.31 CAD/shares 10-Q · filed 2020-08-10 | 12.31 CAD/shares 10-Q · filed 2021-08-06 | ||||
| 2020-03-31 | 19.83 CAD/shares 10-K · filed 2022-05-31 | |||||
| 2019-12-31 | 14.58 CAD/shares 10-Q · filed 2021-02-09 | |||||
| 2019-09-30 | 22.57 CAD/shares 10-Q · filed 2020-11-09 | |||||
| 2019-06-30 | 28.58 CAD/shares 10-Q · filed 2020-08-10 | |||||
| 2019-03-31 | 24.98 CAD/shares 10-K · filed 2021-06-01 | |||||
| 2018-03-31 | 8.88 CAD/shares 10-K · filed 2020-06-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |